Equifax (NYSE:EFX) Issues Q4 2024 Earnings Guidance

Equifax (NYSE:EFX) issued an update on its fourth quarter 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.080-2.180 for the period, compared to the consensus earnings per share estimate of 1.830. The company issued revenue guidance of $1.4 billion-$1.5 billion, compared to the consensus revenue estimate of $1.4 billion. Equifax also updated its FY 2024 guidance to 7.250-7.350 EPS.

Equifax Stock Down 0.1 %

NYSE EFX opened at $289.95 on Thursday. The company has a quick ratio of 0.79, a current ratio of 0.79 and a debt-to-equity ratio of 1.01. Equifax has a fifty-two week low of $159.95 and a fifty-two week high of $309.63. The business has a 50 day moving average price of $294.89 and a two-hundred day moving average price of $262.68. The stock has a market cap of $35.84 billion, a PE ratio of 64.58, a P/E/G ratio of 2.00 and a beta of 1.58.

Equifax (NYSE:EFX) last announced its earnings results on Wednesday, October 16th. The credit services provider reported $1.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.84 by $0.01. The company had revenue of $1.44 billion for the quarter, compared to analyst estimates of $1.44 billion. Equifax had a return on equity of 18.88% and a net margin of 10.67%. Equifax’s quarterly revenue was up 9.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.76 EPS. As a group, sell-side analysts predict that Equifax will post 7.36 EPS for the current fiscal year.

Equifax Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 13th. Investors of record on Tuesday, September 3rd were given a dividend of $0.39 per share. The ex-dividend date was Tuesday, September 3rd. This represents a $1.56 dividend on an annualized basis and a yield of 0.54%. Equifax’s dividend payout ratio is currently 34.74%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. UBS Group started coverage on Equifax in a research report on Tuesday, October 1st. They issued a “buy” rating and a $360.00 target price on the stock. Barclays lifted their price objective on shares of Equifax from $300.00 to $380.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Stifel Nicolaus upped their target price on shares of Equifax from $265.00 to $305.00 and gave the stock a “buy” rating in a research report on Friday, July 19th. JPMorgan Chase & Co. raised their price target on shares of Equifax from $273.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Finally, Morgan Stanley boosted their price objective on Equifax from $250.00 to $271.00 and gave the stock an “equal weight” rating in a research report on Thursday, September 12th. Four analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Equifax presently has an average rating of “Moderate Buy” and an average price target of $307.74.

Insiders Place Their Bets

In other news, EVP Carla Chaney sold 3,000 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $281.85, for a total transaction of $845,550.00. Following the completion of the sale, the executive vice president now owns 10,875 shares in the company, valued at approximately $3,065,118.75. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.57% of the stock is currently owned by company insiders.

About Equifax

Equifax Inc operates as a data, analytics, and technology company. The company operates through three segments: Workforce Solutions, U.S. Information Solutions (USIS), and International. The Workforce Solutions segment offers services that enables customers to verify income, employment, educational history, criminal justice data, healthcare professional licensure, and sanctions of people in the United States; and employer customers with services that assist them in complying with and automating payroll-related and human resource management processes throughout the entire cycle of the employment relationship.